Loading
A phase 1/2 trial of PM8002, Ipilimumab in hepatocellular carcinoma, run by Bristol-Myers Squibb, now recruiting.
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206) is a phase 1/2 interventional study registered as NCT07291076 by Bristol-Myers Squibb, with 198 participants planned, started 2026-03-16 and due to reach its primary completion in 2029-10-15. Interventions recorded: Pumitamig, Ipilimumab. Conditions listed: Hepatocellular Carcinoma (HCC). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares PM8002, Ipilimumab, Bristol Myers Squibb.
Shares Advanced hepatocellular carcinoma (BCLC C), Ipilimumab, Hepatocellular carcinoma.
Shares Advanced hepatocellular carcinoma (BCLC C), Ipilimumab, Hepatocellular carcinoma, Immune checkpoint inhibitors.
Shares Ipilimumab, Bristol Myers Squibb, Immune checkpoint inhibitors.
Shares PM8002, Bristol Myers Squibb.
Shares PM8002, Bristol Myers Squibb.
Shares PM8002, Bristol Myers Squibb, Immune checkpoint inhibitors.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/